A Phase I Study of MEDI5752 in Patients with Renal Cell Cancer


Full Title

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors


The purpose of this study is to assess the safety and effectiveness of the investigational drug MEDI5752 in patients with advanced renal cell carcinoma. Please note that this study at Memorial Sloan Kettering Cancer Center is not open to patients with other types of cancer.

MEDI5752 is given intravenously (by vein) every three weeks. It works by activating the patient’s immune system to fight the cancer.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic renal cell cancer with a clear cell component as noted in the pathology report.
  • At least 3 weeks must pass between the completion of prior treatment and receipt of MEDI5752.
  • Patients may have received up to two prior treatment regimens with tyrosine kinase inhibitors (such as sunitinib, pazopanib, axitinib, or cabozantinib).
  • Prior immunotherapy is not permitted.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Martin Voss at 646-888-4721.